JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4376
PUT
Enphase Energy
ENPH
$4.48B
| $442K | ﹤0.01% |
2,100
-225,800
| -99% | -$48.9M |
2022 Q4
1 quarter
|
|
4377
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$11.1B
| $440K | ﹤0.01% |
14,848
-1,957,243
| -99% | -$57.7M |
2014 Q2
35 quarters
|
|
4378
Amneal Pharmaceuticals
AMRX
$7.07B
| $439K | ﹤0.01% |
315,337
+8,295
| +3% | +$16.5K |
2018 Q2
19 quarters
|
|
|
CMRX
4379
DELISTED
Chimerix, Inc.
CMRX
| $439K | ﹤0.01% |
349,229
-143,476
| -29% | -$234K |
2013 Q2
39 quarters
|
|
4380
Tortoise North American Pipeline ETF
TPYP
$854M
| $439K | ﹤0.01% |
18,048
-54,731
| -75% | -$1.36M |
2019 Q3
14 quarters
|
|
4381
ARK Space & Defense Innovation ETF
ARKX
$768M
| $439K | ﹤0.01% |
31,313
+3,416
| +12% | +$46.7K |
2021 Q2
7 quarters
|
|
4382
Accel Entertainment
ACEL
$888M
| $438K | ﹤0.01% |
48,022
-2,495
| -5% | -$22.4K |
2020 Q2
11 quarters
|
|
4383
Vita Coco
COCO
$3.15B
| $437K | ﹤0.01% |
22,253
+5,428
| +32% | +$85K |
2021 Q4
5 quarters
|
|
4384
Senseonics Holdings Inc
SENS
$527M
| $435K | ﹤0.01% |
30,605
+5,702
| +23% | +$115K |
2017 Q4
21 quarters
|
|
4385
ProFrac Holding
ACDC
$888M
| $434K | ﹤0.01% |
34,282
-660
| -2% | -$12.8K |
2022 Q3
2 quarters
|
|
4386
Vaalco Energy
EGY
$608M
| $434K | ﹤0.01% |
95,979
+20,069
| +26% | +$91.7K |
2021 Q4
5 quarters
|
|
4387
Grupo Aeroportuario Centro Norte
OMAB
$4.57B
| $433K | ﹤0.01% |
4,834
| – | – |
2016 Q3
26 quarters
|
|
4388
Pan American Silver
PAAS
$19B
| $433K | ﹤0.01% |
23,786
+4,564
| +24% | +$78.4K |
2014 Q1
36 quarters
|
|
4389
Universal Electronics
UEIC
$71.5M
| $433K | ﹤0.01% |
42,692
+934
| +2% | +$16.3K |
2013 Q2
39 quarters
|
|
4390
CALL
Air Products & Chemicals
APD
$62.6B
| $431K | ﹤0.01% |
1,500
-700
| -32% | -$204K |
2022 Q1
4 quarters
|
|
|
EBIX
4391
DELISTED
Ebix Inc
EBIX
| $430K | ﹤0.01% |
32,534
+6,713
| +26% | +$117K |
2016 Q4
25 quarters
|
|
4392
Xtrackers S&P 500 ESG ETF
SNPE
$2.86B
| $430K | ﹤0.01% |
11,548
+11,528
| +57,640% | +$416K |
2022 Q4
1 quarter
|
|
4393
CALL
Wheaton Precious Metals
WPM
$62.5B
| $429K | ﹤0.01% |
8,900
-3,700
| -29% | -$162K |
2022 Q2
3 quarters
|
|
4394
Anika Therapeutics
ANIK
$256M
| $428K | ﹤0.01% |
14,936
+3,672
| +33% | +$109K |
2015 Q4
29 quarters
|
|
|
HQH
4395
abrdn Healthcare Investors
HQH
$1.11B
| $428K | ﹤0.01% |
24,254
-14,588
| -38% | -$265K |
2022 Q3
2 quarters
|
|
|
PTVE
4396
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
| $427K | ﹤0.01% |
53,395
+4,499
| +9% | +$46.3K |
2020 Q3
10 quarters
|
|
4397
Q32 Bio
QTTB
$241M
| $426K | ﹤0.01% |
22,963
| – | – |
2018 Q1
20 quarters
|
|
|
AKRO
4398
PUT
DELISTED
Akero Therapeutics
AKRO
| $425K | ﹤0.01% |
+11,100
| New | +$495K |
2023 Q1
0 quarters
|
|
4399
American Public Education
APEI
$846M
| $423K | ﹤0.01% |
78,069
-5,100
| -6% | -$53.5K |
2016 Q2
27 quarters
|
|
4400
FT Vest US Equity Enhance & Moderate Buffer ETF September
XSEP
$100M
| $420K | ﹤0.01% |
12,963
| – | – |
2022 Q4
1 quarter
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.